Telehealth partners for Eli Lilly continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long shortage of ...

In April 2025, Eli Lilly and Company (Lilly) filed lawsuits in the U.S. District Court for the Northern District of California against telehealth companies, alleging the companies sell illegal ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Pharmaceutical company Eli Lilly warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.